Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Haeseong Park(Brigham and Women's Hospital), Geoffrey I. Shapiro(Brigham and Women's Hospital), Jason S. Starr(Jacksonville College), Amy Gubits, Parminder Singh(WinnMed), Afzal Ahrorov(The University of Texas MD Anderson Cancer Center), Satya N. Das(Vanderbilt University Medical Center), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Xīn Gào(Qingdao University), Denice Hickman(Agios Pharmaceuticals (United States)), Muhammad Furqan(University of Iowa), Amit Mahipal(Dana-Farber Cancer Institute)
Cited by 3
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k